Hong Kong-listed cancer screening start-up New Horizon Health to leverage AstraZeneca’s marketing muscle in China push

Hong Kong-listed Chinese colorectal cancer screening start-up New Horizon Health has partnered with UK-based AstraZeneca to sell its molecular test in China.
( read original story …)

---